New Delhi: The skyrocketing popularity of glucagon-like peptide-1 receptor (GLP-1R) drugs has led to significant market growth in recent years. Novo Nordisk and Eli Lilly are set to dominate the GLP-1R market, collectively capturing 94 per cent of the total projected sales for 2030, according to estimates from GlobalData, a data analysis firm.
GlobalData reports that the 11 approved drugs in the GLP-1R category generated $37.2 billion in 2023, establishing them as one of the most lucrative therapy classes. Sales of GLP-1R products are forecast to increase fourfold, reaching an estimated $142 billion by 2030.
Jasper Morley, Pharma Analyst at GlobalData, said, “Novo Nordisk and Eli Lilly accounted for nine of the approved GLP-1R products in 2023, encompassing 99% of the sales. In 2023, Novo Nordisk’s Ozempic and Wegovy generated $13.9 billion and $4.6 billion, respectively, while Eli Lilly’s Trulicity and Mounjaro generated $7.1 billion and $5.1 billion.”
“By 2030, Eli Lilly is expected to surpass Novo Nordisk, becoming the leading company in GLP-1R sales with $67.7 billion. Eli Lilly is projected to market the two top-selling GLP-1R products in 2030, with Mounjaro forecast to generate $27.4 billion and Zepbound $27.3 billion. Novo Nordisk is expected to follow closely, with Ozempic generating $22.4 billion of the company’s $65 billion portfolio. Combined, the GLP-1R portfolios for these companies are forecast to generate $133 billion in 2030,” Morley added.
